Cellenkos

Private

#Autoimmune Diseases #Amyotrophic Lateral Sclerosis #Inflammatory Disorders

Clinical-stage biotech developing allogeneic umbilical cord blood-derived T-regulatory cell therapies for autoimmune diseases and inflammatory disorders.

Company Info

Sector:Cell Therapy

Headquarters:Houston, Texas, USA

Founded:2016

Website:cellenkosinc.com/

Upcoming Milestones & Key Dates

2026-Q4

Clinical

CK0803 ALS Phase 1 data update

Clinical Development Pipeline

CK0803

Target: T-regulatory cells

Amyotrophic Lateral Sclerosis

Preclinical

Phase 1

Phase 2

Phase 3

Approved

CK0804

Target: T-regulatory cells

COVID-19 ARDS

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Simrit Parmar

Founder and CEO

Katie Smith

COO

Careers & Job Openings

See all open roles

Various

Houston, TX

Apply Now →